Health Condition 1: C679- Malignant neoplasm of bladder, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patients treated at TMC, Mumbai after 1/1/2016 Age is more than 18 Urothelial carcinoma of bladder with one or more of the following subtype(s): Micropapillary Squamous differentiation Glandular differentiation Sarcomatoid Small cell/ Neuroendocrine Plasmacytoid Nested Tubular and microcystic Lymphoepithelioma-like Giant cell Clear cell Poorly differentiated
Exclusion criteria
Exclusion criteria: Patients with pure urothelial carcinoma, lymphoma, and other rare pathology will be excluded. Patients with presence of metastasis to the bladder from other primary organs will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS) and disease-free survival (DFS) in patients with subtypes of urothelial carcinoma of the bladder, analysed according to histological subtype and treatment modality.Timepoint: Overall survival and disease-free survival will be assessed retrospectively from the date of diagnosis or definitive treatment (TURBT or cystectomy) until the date of last follow-up or death, over the entire follow-up period (January 2016 to December 2024). | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment response, subtype-wise & treatment-based oncological outcomes, recurrence patterns, & pathological prognostic factors influencing survival in patients with subtypes of urothelial carcinoma of the bladder.Timepoint: Baseline (at diagnosis), & during follow-up at 1 year, 3 years, & 5 years from definitive treatment (TURBT or cystectomy), or until recurrence, last follow-up, or death, whichever occurs first. | — |
Countries
India
Contacts
Public ContactDr GAGAN PRAKASH
Tata Memorial Hospital
Outcome results
None listed